Multiple myeloma is a hematological cancer, characterized by the neoplastic proliferation of a single clone of plasma cell producing a monoclonal protein. The incidence of multiple myeloma increases with age. The median age ad diagnosis is between 63 and 70 years old. The major clinical manifestations of multiple myeloma are related to loss of bone. This bone loss often leads to pathologic fractures, spinal cord compression, hypercalcemia and bone pain. Other symptoms of multiple myeloma are anaemia, leucopenia, thrombocytopenia, hyperproteinemia with decreased serum albumin, elevated serum C-reactive protein (CRP) and kidney dysfunction. Patients suffer from multiple myeloma often require analgesics, such as paracetamol and weak or strong opioids, but nonsteroidal anti-inflammatory drugs (NSAIDS) are contraindicated.

The authors presents a case of the 62-years old man with myeloma multiple, who had chronic pain in the thoracic spine, nonspecific laboratory findings: macrocytic anaemia, without hypercalcemia and elevated serum CRP. Kidney function was normal.

Krismer M., van Tulder M.: Low back pain (non specific); Best Practice&Research Clinical Rheumatology; 2007; 21: 77-91.

Domżała T.M.: Neurologiczne zespoły bólowe wieku podeszłego, Ból 2000; 1: 12-16.

Deyo R.A., et al.: What can the history and physical examination tell us about low back pain? JAMA, 1992; 268: 760-765.

Verrillis P., Vivan D.: Interventions in chronic low back pain. Australian Family Physician 2004; 33: 421-426.

Hutchinson A., et al.: Clinical guidelines for the management of acute low back pain. London, Royal College of General Practitioners, 1999.

Dmoszyńska A.: Gammapatie monoklonalne w Choroby Wewnętrzne, red. A. Szczeklik Medycyna Praktyczna 2006; 1537-1543.

Bruno B, Rotta M, Patriarca F et al.: Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009; 113: 3375-82.

Bensinger W: Stem cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 2008; 26: 480-492.

Rotta M, Storer BE, Sahebi F et al.: Long term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantations and nonmyeloablative allografting. Blood 2009; 113: 3383-3391.

Kumar SK: Multiple myeloma-current issues and controversies. Cancer Treat Rev 2010; 36: 53-11.

Lacy MP, Hayman SR, Gertz MA et al.: Pomalidomide plus-low dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009; 27: 5007-5014.

Vij R, Wang J, Orlowski RZ et al.: Carfilzomib a novel proteasome inhibitor for relapsed or refractory multiple myeloma is associated with minimal peripheral neuropathic effects. Blood 2009; 114: abstr. 430.

Kumar SK, Rajkumar SV, Dispenzieri A et al.: Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.

Dmoszyńska A, Kraj M, Walter-Croneck A et al.: Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznania i leczenia szpiczaka plazmocytowego. Acta Haemat Pol 2009; 40: 747-776.